Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response
NCT ID: NCT03767452
Last Updated: 2018-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
20 participants
INTERVENTIONAL
2018-10-04
2020-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single-Arm
Xiaflex® 0.58 mg, 2 injections separated by 1 to 3 days, repeated after 6 weeks for up to 4 treatment cycles.
Xiaflex® 0.58 mg
0.25 mL injections.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xiaflex® 0.58 mg
0.25 mL injections.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male aged ≥18 years old at screening.
3. Previously received Xiaflex® treatment and had a partial or complete response.
* Partial response is defined as receiving ≤ 4 cycles of Xiaflex® and achieving a penile curvature of ≥ 15 degrees and \< 90 degrees.
* Complete response is defined as receiving ≤ 4 cycles of Xiaflex® and achieving a penile curvature of \< 15 degrees.
4. Has a diagnosis of Peyronie's disease with a penile curvature of ≥ 30 and ≤ 90 degrees at the screening visit.
5. Has a penile curvature of at ≥ 30 degrees in the dorsal, lateral, or dorsal/lateral plane at the screening visit. It must be possible to delineate the single plane of maximal curvature for evaluation during the study.
6. Able and willing to comply with restrictions where intercourse or any other sexual activity is prohibited during each treatment cycle and for at least 2 weeks after each injection cycle.
7. Able and willing to perform home modeling sessions between injection cycles.
8. Is in good health based on medical history evaluation and in the judgment of the principal investigator.
Exclusion Criteria
2. Previous allergic reaction to XIAFLEX®.
3. Has any of the following conditions:
* Chordee in the presence or absence of hypospadias
* Thrombosis of the dorsal penile artery and or vein
* Infiltration by a benign or malignant mass resulting in penile curvature
* Infiltration by an infectious agent, such as lymphogranuloma venereum
* Ventral curvature from any cause
* Presence of an active sexually transmitted disease
* Known active hepatitis B or C
* Known human immune deficiency virus (HIV)
4. Has previously undergone surgery for Peyronie's disease.
5. Has an erection which, in the opinion of the investigator, is insufficient to accurately measure the subject's penile deformity after administration of the prostaglandin E1 (PGE1), Trimix®, or similar erection inducing agent.
6. Has a calcified plaque that, in the opinion of the investigator, would prevent proper administration of the study medication.
7. Has an isolated hourglass deformity of the penis.
8. Has a plaque causing a curvature of the penis located proximal to the base of the penis where injection of local anesthetic would interfere with the injection of Xiaflex®.
9. Has received intralesional or injection therapy for Peyronie's disease including interferon, verapamil, or Xiaflex® \< 6 months prior to screening.
10. Has used antiplatelet or anti-coagulants (e.g. coumadin, Plavix®, Eliquis®, Effient®) within 7 days prior to each Xiaflex® injection. Daily aspirin of 81 mg is acceptable.
11. Has had extracorporeal shock wave therapy (ESWT) for the correction of Peyronie's disease within the 6 months prior to screening or plans to have ESWT at any time during the study.
12. Has uncontrolled hypertension as determined by the investigator.
13. Has a recent history of stroke, bleeding, or other significant medical condition which, in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
14. Has a planned surgical procedure during anticipated study participation.
15. Is unwilling or unable to cooperate with the requirements of the study including completion of all scheduled study visits.
16. Has received investigational drug or treatment within 30 days of the first dose Xiaflex®.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Endo Pharmaceuticals
INDUSTRY
Manhattan Medical Research Practice, PLLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jed Kaminetsky, MD
Role: PRINCIPAL_INVESTIGATOR
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Manhattan Medical Research Practice, PLLC
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Harper Scott
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MMR032018
Identifier Type: -
Identifier Source: org_study_id